IDH1 and acute myeloid leukemia: The best-known inhibitor of mutant IDH1 is ivosidenib (AG-120, Tibsovo®), which was approved by the FDA on 20 July 2018, for the treatment of adults with relapsed or refractory AML with a susceptible IDH1 mutation based on a clinical trial (NCT02074839).